Jefferies Maintains Bullish Stance on ARIAD (ARIA) After ASCO

June 3, 2013 9:13 AM EDT Send to a Friend
Get Alerts ARIA Hot Sheet
Price: $5.76 -0.69%

Rating Summary:
    10 Buy, 12 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 13 | New: 40
Trade ARIA Now!
Join SI Premium – FREE
Jefferies reiterated their Buy rating and $25 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) following ASCO.

Analyst Eun K. Yang comments, "Updated AP'113 Ph1/2 data in NSCLC at ASCO shows promise in ALK+ pts. However, its clinical activity is uncertain for T790M-mutant EGFR pts; data from recently started Ph2 expansion cohort at ESMO (9/27-10/1/13, likely n=~10/20) should provide an answer to its therapeutic potential, if any. Iclusig Tx is durable, with ~65% of CP-CML pts remaining on drug at median FU of 36.5 months & median duration of response not yet reached."

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $18.34 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment